Skip to main content

Table 3 Effects of in vivo administration of infliximab on BD patients with active disease

From: Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity

 

BD

pre-infliximab

BD

post-infliximab

P

Serum Granzyme mOD

715 ± 74

207 ± 72

< 0.001

EF of Vγ9/Vδ2

256 ± 90

80 ± 44

< 0.001

CD45RO-CD27+ (%)

4.4 ± 3.6

21 ± 2.6

< 0.01

CD45RO+CD27+ (%)

9.2 ± 7.5

61.4 ± 11.1

< 0.001

CD45RO+CD27- (%)

54 ± 12

7 ± 3

< 0.0001

CD45RO-CD27- (%)

20.6 ± 22

6 ± 6.5

< 0.001

  1. BD, Behçet's disease.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us